Heart Failure
Clinical Indications and Science Learning Series
Clinical Trials & Science
Episodes
Long-term Outcomes of Endovascular Baroreflex Amplification in Symptomatic Patients With HFrEF
11 min.
Transcatheter Pulmonary Artery Banding in Chronic Heart Failure: Results From an Early Feasibility Study
11 min.
Current Clinical Evidence Following TR Interventions
20 min.
The PRELIEVE Trial: Responder Analysis in the HFpEF Subgroup Regarding Baseline PVR, Pacemaker and Pressure Gradients
11 min.
No-Implant Interatrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Six-Month Outcomes From Multi-Center Pilot Feasibility Studies
12 min.
Pulmonary Artery Denervation: Innovative Pulmonary Hypertension Therapies
9 min.
Next Trials in LVAD Therapy
8 min.
Baroreflex Activation Therapy (BAT) in Patients With Heart Failure and a Reduced Ejection Fraction (BeAT-HF): Long-Term Outcomes
9 min.
Vagal Nerve Stimulation (ANTHEM)
8 min.
Aortic Arch Simulation (Enopace)
8 min.
Cardiac Contractility Modulation for HFrEF and HFpEF: Impulse Dynamics
9 min.
Splanchnic Nerve Denervation for HFrEF and HFpEF
8 min.
Mechanical Stimulation of the Carotid Sinus: MobiusHD
5 min.
Obesity in Heart Failure with Preserved Ejection Fraction: Insights from the REDUCE LAP-HF II Trial
10 min.
Physician-Directed Patient Self-Management in Heart Failure Using LA Pressure: Initial Insights From VECTOR-HF I & IIa Studies
11 min.
Impact of the V-Wave® Ventura® Interatrial Shunt Device on Right and Left Ventricular Structure and Function: Complete 12-Month Results of the RELIEVE-HF Roll-in Cohort
10 min.
Longer Term Effects of Hemodynamic Monitoring on Outcomes: A Combined Data Analysis of Patients with HFrEF in CHAMPION, GUIDE-HF, and LAPTOP-HF
11 min.
Exercise Capacity and Health-Related Quality of Life With Furoscix: Data From the AT HOME Pilot Study
8 min.
Blood Volume Analysis Guided Heart Failure Management: A Pilot Randomized Controlled Trial
9 min.
Heart Failure Journal Editors' Forum: JACC - Heart Failure
7 min.
Use of Remote Speech Analysis to Detect Worsening Heart Failure Events in Ambulatory Heart Failure Patients
11 min.
Clinical Profiling in Patients With HFpEF Phenotype Exhibiting Elevated Resting Supine and Normal Exercise Upright Pulmonary Capillary Wedge Pressures
11 min.
Influence of Body Surface Area, and Ventricular Dimensions on Impella 5.5 Outcomes
9 min.
Influence of Serum Potassium on the Decongestive Potential of Spironolactone: Insights from the ATHENA-HF Trial
9 min.
Pulmonary Artery Catheter Use in Patients with Heart Failure Cardiogenic Shock (HF-CS): An Analysis from the Cardiogenic Shock Working Group (CSWG)
9 min.
Heart Failure Journal Editors' Forum: Structural Heart
7 min.
Heart Failure Journal Editors' Forum - JACC: Clinical Electrophysiology
7 min.
Heart Failure Journal Editors' Forum - Circ: Heart Failure
6 min.
Heart Failure Journal Editors' Forum: JACC: Basic to Translational Science
7 min.
Heart Failure Journal Editors' Forum: JCF
7 min.
Heart Failure Journal Editors' Forum: Journal of Heart and Lung Transplant
8 min.
Pros and Cons of the Win Ratio as the Primary Endpoint for Pivotal Heart Failure Trial
10 min.
Strengths and Limitations of a Two-Phase (6-Month Intermediate Endpoints & 12-18 Month Mortality and Heart Failure Hospitalization) Design for Trials on Chronic Heart Failure Devices
10 min.
Regulatory Aspects for Chronic Heart Failure Devices - FDA Perspective
10 min.
Regulatory Questions on Device Trials for Acute Decompensated Heart Failure - FDA Perspective
6 min.
Now is Not Soon Enough: Why Improving Patient Diversity in HF Trials is a Key Priority
10 min.
FDA Guidance on Meaningful Representation in Clinical Trials
22 min.
Training Investigators to Advance Diversity and Inclusion
9 min.
Recruitment Strategies for Vulnerable and Marginalized Trial Participants
9 min.
The Leaders of the Pack: Why Improving Investigator Diversity in Heart Failure Trials is a Key Priority
17 min.
Clinically Meaningful and Practical Pivotal Trial Endpoints for Devices in Acute Decompensated Heart Failure
9 min.
Hot Topics on Regulatory Issues in Caridiogenic Shock - FDA Perspective
8 min.
How Narrow or Broad Should Enrollment Criteria Be in Trials on Cardiogenic Shock to Achieve Clinically Interpretable Results?
7 min.
How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial on Cardiogenic Shock? What Are The Key Treatment Protocol Elements?
9 min.
Application of Exception from Informed Consent to a Multicenter Cardiogenic Shock Trial
9 min.
Debate: Revascularization in Chronic Heart Failure after REVIVED - Revascularize!
5 min.
Debate: Revascularization in Chronic Heart Failure after REVIVED - is GDMT enough?!
4 min.
Latest Data From REVIVED
7 min.
Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: One Year Results of the REBALANCE-HF Roll-in Cohort
7 min.
Transcatheter Pulmonary Artery Banding In Chronic Heart Failure [HFrEF]: Results From the First-in-Human Study
8 min.
Acute Decompensated HF Trials: Who Should be Enrolled and What Should the Study Endpoints Be?
15 min.
Wearable HF Monitoring Devices: Landscape Overview, Patient Indications, and Implementation Science
25 min.
The Conundrum of Clinical Trials in Cardiogenic Shock
16 min.